Queensland’s Microbio has become an unlisted public company in a move to position the biotechnology
scale-up for expansion into international markets. This move to public company status coincided with the company’s recent CE Mark of approval for the use of its revolutionary Bloodstream Infection test, Microbio InfectID-BSI in Europe.
Read more in the media release: 220705_Microbio_announces_new_status_as_an_Unlisted_Public_Company
Australian biotech scaleup, Microbio is set to break into the European market with its flagship
bloodstream infection (BSI) test. Following extensive clinical evaluation trials, the company has been granted a CE Mark, which has opened the door for distribution and use in Europe.
Read more in the media release: 220614_Australian_bloodstream_infection_test_cleared_for_sale_in_Europe
Queensland biotechnology company Microbio expects clinical evaluation trials of its InfectID-BSI tests to be completed next month, prior to launching in the European market.
US based Landrich Group is managing the trials at four locations in the USA, South America, India and Australia, undertaking a performance evaluation of Microbio InfectID assays.
Read more in the media release: 220412_Independent assessment of Microbio’s BSI test expected to be completed in May
Microbio CEO Paul Carboon talks with Simon Thomsen from Startup Daily about the capital raise that will help to facilitate the launch of our revolutionary bloodstream infection test.
Microbio is pleased to announce that following positive domestic pilot study results, its market entry plans for its flagship InfectID-BSI test, which has the potential for significant improvement in detecting bloodstream infection and sepsis, the world’s biggest killer.
Bloodstream infection (BSI) and sepsis result in 11 million deaths annually, killing more people than all forms of
cancer. InfectID-BSI is an in vitro diagnostic test which significantly improves patient outcomes by telling clinicians
within three hours of taking a blood sample which infection to treat.
Read more in the media release: 220328_Microbio_announces_capital_raise_to_launch_revolutionary_bloodstream_infection_test_in_Europe
Australian biotech company Microbio has been awarded an Australian Government Advanced Manufacturing Growth Centre (AMGC) co-investment of $407,000 to enable the company to establish sovereign manufacturing capabilities in Australia for a test to identify potential biological threats.
The company will manufacture specific oligonucleotides, a unique component used in its product suite, which includes InfectID-BSI, InfectID-COVID and InfectID-SSBA: its patented one-tube, seven-pathogen test to rapidly detect Security Sensitive Biological Agents (SSBAs).
Read more in the Media Release
International medical device and pharmaceuticals consultant Dr Raffaella Giardino has joined the team at Microbio to drive commercialisation of the product suite in Europe.
Read more in the announcement: 211214_Microbio_welcomes_Raffaella_Giardino
Microbio is pleased to announce it has appointed a distributor in India for its range of COVID-19 tests.
The appointment of Indian firm, BioGTech, follows the approval of Microbio’s COVID-19 tests by the Indian Council of Medical Research (ICMR), and validation testing by Rajiv Gandhi Centre for Biotechnology (RGCB). The first deliveries to India are expected to be made in coming weeks.
Find out more in the media release: 211209_Microbio_prepares_for_first_deliveries_in_India
Microbio has moved into new laboratories at Brisbane’s Translational Research Institute (TRI) with the aim of eventually setting up domestic manufacturing capability.
More information can be found in the media release.
211019_Microbio_moves_toward_sovereign_manufacturing_of_diagnostic_tests
Microbio is pleased to announce its two COVID-19 tests have been approved for sale in Europe under the IVD Directive 98/79/EC.
More information can be found in the media release.